Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States, Chile, and Peru has not been known. METHODS: In this ongoing, double-blind, randomized, placebo-controlled, phase 3 clinical trial, we investigated the safety, vaccine efficacy, and immunogenicity of two doses of AZD1222 as compared with placebo in preventing the onset of symptomatic and severe coronavirus disease 2019 (Covid-19) 15 days or more after the second dose in adults, including older adults, in the United States, Chile, and Peru. RESULTS: A total of 32,451 participants underwent randomization, in a 2:1 ratio, to receive AZD1222 (21,635 participants) or placebo (10,816 participants). AZD1222 was safe, with low incidences of serious and medically attended adverse events and adverse events of special interest; the incidences were similar to those observed in the placebo group. Solicited local and systemic reactions were generally mild or moderate in both groups. Overall estimated vaccine efficacy was 74.0% (95% confidence interval [CI], 65.3 to 80.5; P<0.001) and estimated vaccine efficacy was 83.5% (95% CI, 54.2 to 94.1) in participants 65 years of age or older. High vaccine efficacy was consistent across a range of demographic subgroups. In the fully vaccinated analysis subgroup, no severe or critical symptomatic Covid-19 cases were observed among the 17,662 participants in the AZD1222 group; 8 cases were noted among the 8550 participants in the placebo group (<0.1%). The estimated vaccine efficacy for preventing SARS-CoV-2 infection (nucleocapsid antibody seroconversion) was 64.3% (95% CI, 56.1 to 71.0; P<0.001). SARS-CoV-2 spike protein binding and neutralizing antibodies increased after the first dose and increased further when measured 28 days after the second dose. CONCLUSIONS: AZD1222 was safe and efficacious in preventing symptomatic and severe Covid-19 across diverse populations that included older adults. (Funded by AstraZeneca and others; ClinicalTrials.gov number, NCT04516746.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Modified Poisson Regression Approach to Prospective Studies with Binary Data
Zou, G. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh090 · Cited by 9,615
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104840 · Cited by 2,259
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
Schultz, N. H., Sørvoll, I. H., Michelsen, A. E., Munthe, L. A., Lund-Johansen, F., Ahlen, M. T., Wiedmann, M., Aamodt, A.-H., Skattør, T. H., Tjønnfjord, G. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104882 · Cited by 1,452
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32466-1 · Cited by 1,324
Self-citationEfficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102214 · Cited by 1,257
Self-citationMadhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · doi:10.1101/2021.02.10.21251247 · Cited by 1,257
Self-citationVoysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00432-3 · Cited by 1,119
Self-citation
Research works printed but not linked: 1
- COVID-19 Vaccine Tracker. Oxford/AstraZeneca: AZD1222. 2021 (https://covid19.trackvaccines.org/vaccines/4/).
Cited by
Items 601–670 of 670
Thorpe, R. J., Bruce, M. A., Beech, B. M., Heitman, E., & Norris, K. C. (2024) · American Public Health Association eBooks · doi:10.2105/9780875533476ch09
Frequency of SARS-CoV-2 Infections among Healthcare Workers in Germany: 3-Year Follow-Up Study
Stammkötter, C., Thümmler, L., Korth, J., Marenbach, B., Braß, P., Horn, P. A., Lindemann, M., Dittmer, U., Witzke, O., Rohn, H., et al. (2024) · Infectious Disease Reports · doi:10.3390/idr16040047
“The vaccines offered effective protection against severe illness [29–31] and significantly reduced the infectiousness of vaccinated and/or previously infected individuals compared to those without any history of vaccination or infection [32,33].”
BackgroundCOVID-19-un PROFİLAKTİKASI ÜÇÜN AZD1222 VƏ RAD26-S KOMBİNASİYASININ TƏTBİQİ
Гасанов, А. Б., Гулиева, Н. М., Исмаилова, Г. А., Гулиев, З. Г., Исмаилова, С. А., Галимова, Л. Г., Mamedov, R. F., & Джаббарова, А. М. (2023) · Azerbajdžanskij medicinskij žurnal · doi:10.34921/amj.2023.4.016
Vaccination against COVID-19 in a post-pandemic era
Neto, F. L., Ceccato, A., & Ranzani, O. (2024) · European Respiratory Society eBooks · doi:10.1183/2312508x.10020223
Modelling antibody dynamics in humans after different Ad26.COV2.S vaccination schemes
Dari, A., Ruixo, J. J. P., Gars, M. L., Struyf, F., & Jacqmin, P. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16251
“For the 4 years after the start of the COVID-19 pandemic different vaccines have been deployed 5 – 9 and the humoral response time course appeared to be dependent on several factors, such as the vaccine-platform (or formulation) and individual COVID-19 vaccination history, including the dose level…”
Eviatar, T., Ziv, A., Oved, A., Miller‐Barmak, A., Pappo, A., Livny, R., Amarilyo, G., Aviel, Y. B., Naor, R., Pel, S., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126426
The role of COVID-19 vaccination
Lin, E. Y., Behrouzi, B., & Udell, J. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14001-3.00015-7
Fung, S. S.-P. (2024) · Drugs & Therapy Perspectives · doi:10.1007/s40267-024-01124-2
“…symptomatic illness by 74.0% and ↓ severe illness by 100% over a median follow up of 61 day from the second dose (includes Alpha and Beta variants) [19]; AEs include pain, headache, injection site pain and fatigue In real world studies, AZD1222 was slightly less effective than BNT162b2 in…”
InfluentialSyed, A. A., Eqbal, F., Shamsi, H. R., Syed, A. R. S., Zakir, S. J., Fawzy, M., & Khan, K. S. (2024) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2024.102343 · Cited by 1
Gyasi, S. F., Donkoh, E. T., Frempong, S., Asamoah, A., Raji, A. S., Baidoo, R. C., Isaac, W., Essel, D., & Asakiya, H. A. (2024) · Scientific African · doi:10.1016/j.sciaf.2024.e02489
Risk of SARS-CoV-2 infection and adverse outcomes among vaccinated patients with tuberculosis
Chang, R., Chen, S.-Y., Hsieh, T. Y. J., Chen, H.-Y., Wang, S., Hung, Y., & Wei, J. C.-C. (2025) · Public Health · doi:10.1016/j.puhe.2024.09.028
COVID-19 vaccines: A comprehensive review of safety and efficacy
Yan, Z., Yang, M., & Lai, C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19170-1.00028-0
SARS-CoV-2 spike protein in infectivity
Altaie, A. M., Hamdy, R., Husseiny, M. I., & Soliman, S. S. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19170-1.00015-2
Leddin, E. M. (2022) · University of North Texas Digital Library (University of North Texas) · doi:10.12794/metadc1944361
UK cancer vaccine advance – Recognising and realising opportunities
Craddock, C., Earwaker, P., Fittall, M. W., Fontana, E., Ganesh, D., Gerlinger, M., Ghafoor, Q., Jones, R. P., Kunene, V., Lee, L. Y. W., et al. (2025) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2024.5
“In recent years, we have again experienced their transformative benefits, with multiple vaccines effective in preventing illness from SARS-CoV-2 (Monin et al. 2021; Falsey et al. 2021).”
Thanborisutkul, K., Kulalert, P., Methaset, K., Nanthapisal, S., Chunthatikul, T., Phangpanya, N., Charoenying, P., Atsawutmangkru, W., Srijaroen, S., Punyashthira, P., et al. (2025) · Vaccines · doi:10.3390/vaccines13030289 · Cited by 1
“Similarly, Falsey et al. [8] reported that AZD1222 was safe, with low incidences of serious and medically attended adverse events.”
Wan, S.-H., Liang, H.-C., Tsou, H., Wu, H. I., & Wang, S. (2025) · Statistical Methods in Medical Research · doi:10.1177/09622802251319120
“Although a treatment allocation of T : C = 1 : 1 is common in an MRCT, there may be a higher proportion in the treatment arm in some clinical trials.”
González-Sánchez, Ó. A., González-Ortiz, L. J., Sánchez-Peña, M. J., & Pulido, H. G. (2025) · Vaccines · doi:10.3390/vaccines13040363
“Thus, more than 10 million Mexicans in this group were vaccinated and most of them were vaccinated with two-dose schemes of the BNT162b2 (Comirnaty ® ; Pfizer; New York, NY, USA) vaccine [3] or two-dose schemes of the AZD1222 (Vaxzevria ® , AstraZeneca; Cambridge, UK) vaccine [4].”
Xenogenic adenoviral vectors as vaccines
Coughlan, L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-89821-8.00016-4
Barnay, M., Foubert‐Samier, A., Violleau, M., Salort‐Campana, E., Cintas, P., Laforêt, P., Mathis, S., Péréon, Y., Tard, C., Sirma, F., et al. (2025) · Revue Neurologique · doi:10.1016/j.neurol.2025.04.007
Croft, D. P., Johnston, C. J., Branche, A. R., Rich, D. Q., Hopke, P. K., Thevenet-Morrison, K. N., Thurston, S. W., Jusko, T. A., Islam, M. R., Bunce, C. A., et al. (2025) · PLOS Global Public Health · doi:10.1371/journal.pgph.0004609
“The present pilot study, in Western New York leveraged an existing trial of Astra Zeneca (AZ) Phase 3 trial of the ChA-dOx1 vectored COVID vaccine (AZD1222) [18].”
Self-citationBeller, N. S., Beller, M., Murmann, J. J., & Crisp, R. W. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127392
Schlaiß, T. N., Vassilenko, M. D., Kimmel, T., Diessner, J., Wöckel, A., McNeill, R. V., Kittel‐Schneider, S., Kämmerer, U., & Bartmann, C. (2025) · Oncology Research and Treatment · doi:10.1159/000546837
“In the following year, there were also other vaccines available in Germany (Moderna COVID-19 Vaccine/ Spikevax) [9], COVID-19 Vaccine by AstraZeneca (Vaxzevria) [10] and COVID-19 Vaccine Janssen (Johnson & Johnson) [11].”
InfluentialClemens, S. A. C., Bibi, S., Marchevsky, N. G., Aley, P. K., Cappuccini, F., Davies, S. A., Gonzalez, I., Kelly, S. C., Mujadidi, Y. F., Milan, E. P., et al. (2025) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2025.100642
Self-citationCorsini, C. A., Campos, G. R. F., Martins, P. F. D. S., Filgueiras, P. S., Lima, A. E. D. S., Gomes, S. V. C., Curimbaba, C., Lorencini, D. A., Morandi, E., da Silva, V. M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1589733 · Cited by 1
Lim, S. Y., Cha, H. H., Kim, J. Y., Kwon, J., Chang, E., Bae, S., Jung, J., Kim, M. J., Chong, Y. P., Choi, S., et al. (2025) · Infection and Chemotherapy · doi:10.3947/ic.2025.0027
New Vaccine Strategies to Improve, Boost, or Replace BCG
Torracinta, L., Nassanga, B., & Tanner, R. (2025) · Springer eBooks · doi:10.1007/978-3-031-94540-3_5 · Cited by 1
Dhayfule, D., Wu, Y.-H., Ashyani, A., Li, M.-C., Tsai, C.-S., Chen, P., & Nordling, T. E. M. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11289-4
“AZD1222 [30] 0.03 (0.00–0.49) 3.05 3.02 AZD1222 [30] 0.05 (0.01–0.42) 3.23 4.98 AZD1222 [30] 0.16 (0.01–3.96) 0.54 2.48 Ad26.”
InfluentialIdentification of novel genetic biomarkers for ChAdOx1 nCoV-19 mediated immunogenicity
Chou, W., Chang, C., Ting, J., Lin, M., Liao, H.-N., Chou, Y.-C., Wei, C.-Y., Chi, H.-H., Ho, S.-Y., Luo, W.-T., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1622122
Risk factors of COVID-19 breakthrough infection: a case-control test-negative design study
Tejada, G., Pinós, L., Otero‐Romero, S., Borràs-Bermejo, B., Carbonés-Fargas, Í., Antón, A., Andrés, C., & Parés‐Badell, O. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11773-x
“Regarding non-mRNA vaccines, efficacies between 64.3% and 66.1% have been demonstrated [5, 9].”
InfluentialFarouq, M. A. H., Kubiak-Ossowska, K., Qaraghuli, M. M. A., Ferro, V. A., & Mulheran, P. A. (2025) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5c04391
Pallaprolu, N., Aishwarya, D., Dhingra, S., Pandey, K., Velayutham, R., & Peraman, R. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.117215
Yao, M., Wang, P., Wang, M., Zheng, S.-Q., Xu, X.-W., Zhang, Q.-M., Yu, Q., Qin, H.-R., Meng, Y.-B., & Hong, J. (2024) · Research Square · doi:10.21203/rs.3.rs-4240784/v1
Jing, X., Han, M., Wang, X., & Zhou, L. (2023) · Figshare · doi:10.6084/m9.figshare.24089183
Sobczak, M., & Pawliczak, R. (2022) · Figshare · doi:10.6084/m9.figshare.20222722
Wu, X., Xu, K., Zhan, P., Liu, H., Zhang, F., Song, Y., & Lv, T. (2024) · Figshare · doi:10.6084/m9.figshare.25264439
Wu, X., Xu, K., Zhan, P., Liu, H., Zhang, F., Song, Y., & Lv, T. (2024) · Figshare · doi:10.6084/m9.figshare.25264278
Kumari, M., Lu, R.-M., Li, M.-C., Huang, J., Hsu, F.-F., Ko, S.-H., Ke, F.-Y., Su, S.-C., Liang, K.-H., Yuan, J. P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21085242
Liu, Q., Qin, C., Liu, M., & Liu, J. (2021) · Figshare · doi:10.6084/m9.figshare.17010246
Sobczak, M., & Pawliczak, R. (2022) · Figshare · doi:10.6084/m9.figshare.20222719
Cascini, F., Failla, G., Gobbi, C., Pallini, E., Hui, J., Luxi, W., Villani, L., Quentin, W., Boccia, S., & Ricciardi, W. (2022) · Figshare · doi:10.6084/m9.figshare.21152864
Liu, Q., Qin, C., Liu, M., & Liu, J. (2021) · Figshare · doi:10.6084/m9.figshare.17010249
Reis, J. S., Souza, R. M., Junior, H. T. S., Requião‐Moura, L., Pestana², J. O. M., & Foresto, R. D. (2025) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2025.104604
“3,4 In KTRs, the ChAdOx1 vaccine provides comparable antibody titers to mRNA platforms.”
Humoral epitope dominance and immune imprinting by SARS ‐ CoV ‐1 and SARS ‐ CoV ‐2 vaccines
Burnett, D. L., Moxon, A., Aggarwal, A., Jackson, K., Cotter, C. A., Akerman, A., Russell, A. J., KALMAN, R., Langley, D. B., Henry, J. Y., et al. (2026) · Immunology and Cell Biology · doi:10.1111/imcb.70072
Association between COVID-19 vaccine efficacy and epidemic force of infection
Xu, J., Halloran, M. E., Moore, M., Zhang, L., Hyrien, O., Luedtke, A. R., Sahly, H. M. E., Baden, L. R., Goepfert, P., Gray, G., et al. (2026) · npj Vaccines · doi:10.1038/s41541-026-01374-3 · Cited by 1
“We incorporated data from the Moderna COVE trial of mRNA-1273 (CoVPN3001, ClinicalTrials.gov number: NCT04470427) 30,31 , the Astra-Zeneca/Oxford AZD1222 trial of ChAdOx1 nCoV-19 (CoVPN3002, NCT04516746) 32,33 , and the Janssen/Johnson & Johnson ENSEMBLE trial of Ad26.”
Self-citationMiyamoto, N., Yamaguchi, T., Tamada, Y., Yamayoshi, S., Murashita, K., Itoh, K., Imoto, S., Saito, N., Mikami, T., & Nakaji, S. (2026) · Vaccines · doi:10.3390/vaccines14020115
Hudson, A., Borgetti, S. A., Rick, A.-M., Laurens, M. B., Robinson, S. T., Gay, C. L., Baden, L. R., Goepfert, P., Rouphael, N., Sahly, H. M. E., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128380
Self-citationCOVID-19 vaccine-elicited immune mediators and their contribution to protective immunity
Mishra, A., Mallik, S., Chatterjee, S., Naser, S. M., & Mukhopadhyay, S. (2026) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20260725
Alakuş, T. B., & Türkoğlu, İ. (2026) · The Journal of Supercomputing · doi:10.1007/s11227-026-08346-3
“In trials, a group receiving two full doses showed a 62% success rate, while another group receiving a half dose followed by a full dose achieved 90% effectiveness [9].”
Kinganda-Lusamaki, E., Ortega‐Villa, A. M., Camara, D., Haidara, M. C., Blie, J., Coulibaly, N., Dewar, R. L., Kallon, K., Rehman, T., Sereti, I., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-69510-6
COVID-19 Vaccination Strategy and Evidence in Korea
Hwang, Y. H., & Park, W. B. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e114
Analysis and Comparison of the Safety among COVID-19 Vaccines: A Systematic Review
Mostafa, A., & Ehab, H. (2026) · International Journal of Clinical Medical Research · doi:10.61466/ijcmr4020001
“While Pfizer-BioNTech vaccine showed the highest incidence of fever (in case A.R. Falsey et al., trial was added to the analysis), fatigue, and diarrhea events with correlated percentage of 10.23%, 53.53%y, and 10.32%, respectively 24 .”
InfluentialViral variant but not host factors associate with SARS-CoV-2 viral kinetics
Hahn, W. O., Fisher, L. H., Ward, A. M., Grant, S., Yen, C., Randhawa, A. K., Li, X., Ramirez, S., Espy, N., Hural, J., et al. (2026) · Communications Medicine · doi:10.1038/s43856-026-01588-5
Self-citationCorrelates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccine
Janes, H., Fong, Y., Huang, Y., Benkeser, D. C., Kelly, E. J., Hirsch, I., Stanley, A. M., Villafana, T. L., Petropoulos, C. J., Leith, A., et al. (2026) · npj Vaccines · doi:10.1038/s41541-026-01411-1
“11; Supplementary Tables 9 – 11).”
InfluentialSelf-citationMeasuring Humoral Immune Responses to SARS-CoV-2: A Comprehensive Review of Serological Assays
Xue, H., Haynesworth, K., Hempel, H., Kemp, T. J., & Pinto, L. A. (2026) · Vaccines · doi:10.3390/vaccines14050395 · Cited by 1
“The multiplex serology panels have been widely implemented in vaccine evaluation and immunogenicity studies, including large-scale phase 3 clinical trials of mRNA and adenoviral vector vaccines [54,55].”
An engineered CRM197 variant with enhanced stability and efficacy
Hu, E., Cao, C., Chen, C., Zai, X., Wang, Y., Zhai, Y., Li, K., Sang, S., Yu, W., Wen, Y., et al. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.152286
Logical Desiderata on Statistical Inference
Baldi, P., Corsi, E. A., & Hosni, H. (2025) · Outstanding contributions to logic · doi:10.1007/978-3-032-11027-5_6
Shen, Y.-S., Fang, C., Chan, T.-T., Wu, S., Horng, J., Chow, Y., Liao, C., & Liu, C. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128665
The immunogenicity and safety of adenoviral-based vaccines
Gardner, J. (2026) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000001167
The current landscape of Nipah virus vaccines: From antigen design to clinical translation
Li, J., Qu, J., & Xu, K. (2026) · Decoding Infection and Transmission · doi:10.1016/j.dcit.2026.100085
The challenge of COVID-19 on a teratogen information service in AustraliaPreprint
Baker, M., Fotheringham, P., Kennedy, D. S., & Cupitt, D. (2026) · Research Square · doi:10.21203/rs.3.rs-9992781/v1
Liu, X., 安亚玲, Duan, H., Shao, F., Xu, K., Yang, C., Xu, S., Zhou, X., Duan, M., Zheng, T., et al. (2026) · mBio · doi:10.1128/mbio.01464-26
Lee, D. B., Kim, J.-M., Kim, I., No, J. S., Kim, J.-A., Lee, C. Y., Rhee, J. E., Kim, D.-W., Kim, J.-Y., Lee, Y. J., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-63537-5
“COVID-19 originated from the interspecies transmission of the virus from animals to humans 35 .”
Marconato, M., Jäger, S., Tegeler, C. M., Hackenbruch, C., Salih, H. R., Walz, J. S., Federmann, B., & Heitmann, J. S. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1844041
Wang, Z., Gao, J., Bai, R., Yuan, L., Guo, H., Wang, S., Wang, Y., Wu, J., Bu, Q., Guo, H., et al. (2026) · Viruses · doi:10.3390/v18090976
“Consequently, multiple vaccine platforms—including inactivated, live-attenuated, recombinant protein, VLP, mRNA, and viral vector vaccines—were rapidly developed [4–15].”
Zhang, H., Clegg, L., Matthews, S., Chang, Y., Aksyuk, A. A., Francisco, D., Ghosh, S., Soboleva, K., Puri, A., Ramesh, M., et al. (2026) · Infectious Diseases and Therapy · doi:10.1007/s40121-026-01423-3
“Pseudovi‑ rus ‐ based assays, which have been used in previ‑ ous registrational studies of COVID ‐ 19 vaccines and mAbs [17, 48–51], are advantageous over authentic virus assays for comparing neutraliz‑ ing activity across different viral variants.”
Saiki, S., Kuroiwa, M., Hashimoto, K., Nakajima-Yoshida, H., Susai, N., Kato, H., Hamana, S., Ishida, S., Nikaido, E., Toyota, T., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.129177
Prasert, K., Nakphook, S., Kittiwatanachod, J., Ditsungneon, D., Sornwong, K., Naosri, S., Wirachwong, P., Techatanawat, I., Narakorn, P., Surichan, S., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.129230
Metadata
- Authors
- Falsey, A. R., Sobieszczyk, M. E., Hirsch, I., Sproule, S., Robb, M. L., Corey, L., Neuzil, K. M., Hahn, W., Hunt, J., Mulligan, M. J., McEvoy, C., DeJesus, E., Hassman, M., Little, S. J., Pahud, B. A., Durbin, A., Pickrell, P., Daar, E. S., Bush, L., Solis, J., Carr, Q. O., Oyedele, T., Buchbinder, S., Cowden, J., Vargas, S. L., Guerreros Benavides, A., Call, R., Keefer, M. C., Kirkpatrick, B. D., Pullman, J., Tong, T., Brewinski Isaacs, M., Benkeser, D., Janes, H. E., Nason, M. C., Green, J. A., Kelly, E. J., Maaske, J., Mueller, N., Shoemaker, K., Takas, T., Marshall, R. P., Pangalos, M. N., Villafana, T., & Gonzalez-Lopez, A.
- Affiliations
- Columbia University Irving Medical Center (US)
- From the University of Rochester School of Medicine and Dentistry (A.R.F., M.C.K.) and Rochester Regional Health (A.R.F.), Rochester, and Vagelos College of Physicians and Surgeons, New York Presbyterian Columbia University Irving Medical Center, Department of Medicine, Division of Infectious Diseases (M.E.S.) and the New York University Vaccine Center (M.J.M.), New York — all in New York; Biometrics (I.H.) and Infectious Diseases (J.A.G.), Late-Stage Development, Respiratory and Immunology (R.P.M.), Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, United Kingdom; Biometrics (S.S., K.S.) and Infectious Diseases, Late-Stage Development, Respiratory and Immunology (J.M., T. Takas, T.V., A.G.-L.), Translational Medicine, Microbial Sciences, Biopharmaceuticals Research and Development (E.J.K.), and Clinical Development, Early Global Development, Oncology Research and Development (N.M.), AstraZeneca, Gaithersburg, the Walter Reed Army Institute of Research, Silver Spring (M.L.R.), t...
- Corresponding author
- Villafana, Tonya
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-16
- Volume
- 385
- Issue
- 25
- Pages
- 2348-2360
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8522798
- OpenAlex
- W3202234535
- Cited by
- 670
- References
- 21
- Citations by year
- 2026: 33 · 2025: 72 · 2024: 97 · 2023: 185 · 2022: 259 · 2021: 24
- FWCI
- 44.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- United States Government (Agreement No. W15QKN-20-9-1003)
- National Institute of Allergy and Infectious Diseases (UM1 AI 148372, UM1 AI 148450, UM1 AI 148574, UM1 AI 148684, UM1 AI 148684-03, UM1 AI 68614HVTN, UM1 AI 68618, UM1 AI 68619, UM1 AI 68635, UM1 AI 68636)
- Biomedical Advanced Research and Development Authority (W15QKN-21-9-1003)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- ChAdOx1 nCoV-19 vaccine, COVID-19 vaccines, SARS-CoV-2, vaccine efficacy, vaccine safety, immunogenicity, neutralizing antibodies, nucleocapsid antibodies, older adults, adverse events
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, Vaccine Efficacy, ChAdOx1 nCoV-19, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Chile, Double-Blind Method, Female, Humans, Male, Middle Aged, Peru, United States, Young Adult, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.